Piper Sandler initiated coverage of Rapt Therapeutics (RAPT) with an Overweight rating and $95 price target The firm is bullish on the company’s lead-asset, ozureprubart, saying the drug is clinically and commercially de-risked by Xolair. It sees Rapt trading up into the data catalyst in the first half of 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics: De-Risked ‘Bio-Better’ Ozureprubart Underpins Buy Rating and Upside to Target Price
- Rapt Therapeutics initiated with a Buy at TD Cowen
- RAPT Therapeutics: Promising Pipeline and Superior Efficacy of Lead Candidate Ozureprubart
- Rapt Therapeutics participates in a conference call with H.C. Wainwright
- RAPT Therapeutics Announces CMO Departure